Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study
Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…Abstract Number: 2982 • 2018 ACR/ARHP Annual Meeting
Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
ACR abstractBackground/Purpose: Mortality in patients with rheumatoid arthritis (RA) is higher than in the general population. In most studies this becomes apparent only after more…Abstract Number: 1502 • 2018 ACR/ARHP Annual Meeting
Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors
Background/Purpose: We previously identified higher disease activity score assessing 28 joints (DAS28) at baseline, current smoking and no alcohol consumption as clinical predictors for inadequate…Abstract Number: 2985 • 2018 ACR/ARHP Annual Meeting
Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
Background/Purpose: Treat-to-target (T2T) has become a key element in the management of rheumatoid arthritis (RA). Several different measures exist to define the preferred treatment target…Abstract Number: 1889 • 2018 ACR/ARHP Annual Meeting
Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population
Background/Purpose: Glucocorticoids (GC) reduce RA-related disability and joint damage; RA guidelines endorse short term use during DMARD initiation and flares. Long-term high-dose GC exposure (>3…Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose: It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…Abstract Number: 1937 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have lymphocyte dysfunction characterized by deficiency or dysfunction of regulatory T cells (Tregs), which plays crucial roles in immune tolerance. Low dose IL-2…Abstract Number: 1938 • 2018 ACR/ARHP Annual Meeting
A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the efficacy…Abstract Number: 1939 • 2018 ACR/ARHP Annual Meeting
Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail
Background/Purpose: Patients with refractory rheumatoid arthritis (RA) have T-cell dysfunction that associates the activation of mTOR that is inhibited by rapamycin, which has been developed…Abstract Number: 2054 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies like rheumatoid factor (RF), anti-cyclic citrullinated peptide-2 (anti-CCP2), & anti-carbamylated protein (anti-CarP) antibodies. It…Abstract Number: 2344 • 2018 ACR/ARHP Annual Meeting
Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
Background/Purpose: Treatment recommendations in RA emphasize shared decision-making,1 but little is known about patient (pt) perspectives. Through qualitative research, we aim to understand pt preferences…Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…Abstract Number: 516 • 2017 ACR/ARHP Annual Meeting
Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis Patients Who Had Inadequate Response to Biologic Dmards
Background/Purpose: Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been…Abstract Number: 863 • 2017 ACR/ARHP Annual Meeting
Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology
Background/Purpose: Fibroblasts are key effector cells in the persistence of synovial inflammation and joint damage. It is not yet known whether specific subsets of synovial…Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting
Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis
Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »